Real-world effectiveness and factors associated with increased mortality in non-critically ill patients with COVID-19 pneumonia receiving remdesivir.

Lucía Quesada MuñozJorge Fernández Fradejas Hilario Martínez-Barros Marina Sánchez CuervoMiriam Martín RufoMaria Del Rosario Pintor RecuencoCarmen Quereda Rodríguez-NavarroAna María Álvarez-Díaz Javier Saez de la Fuente

Published in: European journal of hospital pharmacy : science and practice (2023)

The 28-day mortality rate in patients treated with remdesivir needing low-flow oxygen therapy was higher than that published in clinical trials. Age and increased oxygen therapy needed after the beginning of treatment were the main risk factors associated with mortality.

Keyphrases

cardiovascular events
clinical trial
risk factors
randomized controlled trial
systematic review
stem cells
coronary artery disease
type diabetes
intensive care unit
replacement therapy
cardiovascular disease
cell therapy
acute respiratory distress syndrome
meta analyses